Menu
ncarol.com
  • Home
  • Financial
  • Business
  • Education
  • Nyse
  • Yacht Buyer
  • Finance
  • Health
  • Stocks
ncarol.com

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
ncarol.com/10291348

Trending...
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - ncarol.com -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on ncarol.com
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
  • K4Connect Launches Team Hub 5.0 — The Intelligent Execution Layer for Senior Living
  • New Book Reveals The Science Of Predictions
  • Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
  • Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
  • LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
  • A Cure In Sight Advances Ocular Melanoma Advocacy During Rare Disease Week 2026 in Washington, DC
  • Craigory Dunn Introduces "The Craig Nice Report," A Bold Response to the AI Music Debate
  • KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
  • New from Regal House Publishing, A Reckoning Up Black Cat Hollow, a psychological crime thriller
  • Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award
  • K4Connect launches K4IQ™, an intelligence layer on FusionOS turning data into actionable insights
  • Atelier 4 Appoints Museum Logistics Expert Heather Haldeman as Senior Client Advisor
  • AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • New Global Standard for Transparency Across Critical Resources and Energy Markets: SMX (Security Matters) PLC (N A S D A Q: SMX)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
  • Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
  • Kiko Nation Launches Mobile App to Modernize Livestock Management and Digital Animal Registry
  • NEW MANAGEMENT BOOK: Creating a Joy-Centric Culture
  • Alternative Singer Songwriter Big Bus Dream, Proudly Releases, Passionate Decay March 25th
  • QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
  • Kaltra Introduces Seasonal Discounts on Replacement Coils for Carrier, York, and Trane Chillers
  • Evolve Construction Mobilizes Commercial Storm Response Across Illinois With AI-Powered Damage Documentation and Public Adjusters Partnership
_catLbl0 _catLbl1

Popular on ncarol.com

  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy - 105
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract
  • Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
  • VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
  • Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
  • 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
  • Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
  • Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers
  • Pastor Saeed Abedini Releases THE TRUTH – Volume 1, A Deeply Personal Story of Faith, Struggle, and Redemption

Similar on ncarol.com

  • Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
  • Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
  • Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
  • NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
  • A Cure In Sight Advances Ocular Melanoma Advocacy During Rare Disease Week 2026 in Washington, DC
  • KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
  • Targeting the Billion-Dollar U.S. Countermeasure Market With AI-Driven Biodefense Platform: Lunai Bioworks (N A S D A Q: LNAI)
  • Forced Psychiatric Hospitalization Fails Vulnerable People: CCHR Urges Repeal Amid Rising U.S. Policies
  • Surging Into High-Performance AI With $AMD Partnership, Patent Expansion, and Strengthened Balance Sheet: Avalon GloboCare Corp. (N A S D A Q: ALBT)
  • QuickTrack by Datalex Transforms Retail Promoter Management with Claude AI and Real-Time Insights
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute